{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"70.8","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"70.8","value":"0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"60.2","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a best overall response of CR or PR and was determined using RECIST version 1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\\<10 mm short axis), PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. 95% confidence interval (CI) was based on Clopper-Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 2\\*10\\^8 plaque forming unit (PFU) once weekly for 4 weeks as an intravenous (IV) push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG000","title":"Part 1A PF-07263689 2*10^8 PFU"},{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 6\\*10\\^8 PFU once weekly for 4 weeks as an IV push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG001","title":"Part 1A PF-07263689 6*10^8 PFU"},{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 20\\*10\\^8 PFU once weekly for 4 weeks as an IV push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG002","title":"Part 1A PF-07263689 20*10^8PFU"}],"paramType":"NUMBER","populationDescription":"Response evaluable set included all participants who received at least one dose of study treatment and had baseline disease assessment \\[or measurable disease at baseline, if applicable\\] and at least one post-baseline disease assessment. Data is not reported for Part 1b as no participants were enrolled and data was not collected.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment until CR or PR (up to maximum follow-up of 10.45 months)","title":"Part 1: Objective Response Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}